可光激活的多器官细胞的连续破坏用于癌症治疗
Wenping Pan1, Hongwei Shao2, Limin Ma2
1School of Materials Science and Engineering, National Engineering Research Center for Tissue Restoration and Reconstruction, Key Laboratory of Biomedical Materials and Engineering of the Ministry of Education, Key Laboratory of Biomedical Engineering of Guangdong Province, Innovation Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, China.
ACS applied materials & interfaces
|July 31, 2023
概括
一种新型的可光激活探头使多个癌细胞器官的连续破坏成为可能,从而提高治疗效率. 这种有机细胞向疗法在体外和体内有望改善癌症治疗结果.
科学领域:
- 生物医学工程 生物医学工程
- 光动力学疗法 光动力学疗法
- 癌症研究 癌症研究
背景情况:
- 针对器官细胞的癌症治疗提供了精确性,但受到单个器官细胞破坏的限制.
- 目前的治疗方法通常表现出有限的疗效,因为它们只针对一个细胞器.
研究的目的:
- 开发一种可光激活的探针,用于癌细胞中多个器官的连续破坏.
- 调查这种新的治疗策略的体外和体内疗效.
- 通过光色彩转换实现实时监测有机细胞破坏.
主要方法:
- 开发一种可光激活的探针,用于测定序列性细胞器的向.
- 在体外对癌细胞根除的评估.
- 在体内瘤生长抑制的评估.
- 使用光成像用于在现场观察连续的有机细胞破坏.
主要成果:
- 可光激活的探针成功地在体外消除了癌细胞.
- 该探针在活体中抑制瘤生长方面表现出有效性.
- 实现了 lysosomes,脂质滴和线粒体的顺序破坏.
- 绿色到红色光转换证实在位器官破坏.
结论:
- 开发的可光激活探头使得癌细胞中的多个器官细胞能够被连续破坏.
- 这种多器官向策略显著提高了治疗疗效.
- 光色彩转换为监测治疗进展提供了可视指标.
- 这种方法为癌症治疗提供了一个新且有效的策略.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Autophagic Cell Death
3.5K
Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


